Hyperbaric Oxygen Therapy Combined Camrelizumab in Patients With Advanced/Metastatic Hepatocellular Carcinoma
The purpose of this study is to explore the efficacy and safety of hyperbaric oxygen therapy plus Camrelizumab as a second-line treatment in patients with advanced hepatocellular carcinoma who have failed at least 1 previous treatment.
Combinational Immunotherapy|Hepatocellular Carcinoma Non-Resectable|Hyperbaric Oxygen Therapy
COMBINATION_PRODUCT: hyperbaric oxygen therapy plus Camrelizumab
Objective Response Rate (ORR) per RECIST v1.1, ORR defined as the proportion of subjects who achieved a complete response (disappearance of all target lesions) or a partial response (â‰¥ 30% decrease in the sum of the longest diameters of target lesions) based on RECIST v1.1., up to 12 months.|Progression-free survival based on RECIST v1.1, Progression-free survival defined as the time from the first day of taking study drug to death or disease progression by RECIST v1.1., Time from first treatment to the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months
Duration of Response Rate per RECIST v1.1, time from the date of CR or PR until PD, up to 12 months|Disease control rate per RECIST v1.1, Disease control rate (DCR)=CR + PR + stable disease, up to 12 months|Overall Survival, Duration from the date of initial treatment with hyperbaric oxygen therapy plus Camrelizumab to the date of death due to any cause., up to 12 months|Number of Subjects with one or more adverse events as assessed by CTCAE 5.0, Safety and tolerability of hyperbaric oxygen therapy plus Camrelizumab as assessed by the frequency, duration, and severity of adverse events, From screening through 30-35 days after end of treatment, up to 12 months
The purpose of this study is to explore the efficacy and safety of hyperbaric oxygen therapy plus Camrelizumab as a second-line treatment in patients with advanced hepatocellular carcinoma who have failed at least 1 previous treatment.